Tamayo Louis Edward 4

What Happened

• Louis Edward Tamayo, Chief Financial Officer of Lexeo Therapeutics (LXEO), received equity awards on February 4, 2026 totaling 271,330 restricted stock units (RSUs): 44,665 RSUs (reported as acquisition) and 226,665 RSUs (reported as derivative acquisition). Each award is reported at $0.00 (these are compensation grants, not open-market purchases).

Key Details

• Transaction date: February 4, 2026; Form 4 filed February 6, 2026.
• Reported amounts/prices: 44,665 RSUs @ $0.00 and 226,665 RSUs (derivative) @ $0.00; total 271,330 RSUs.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes of note:
  • F1/F2: These awards are RSUs. F1: 25% of the RSUs vest on February 15, 2027, then 1/16th vest on the issuer’s standard quarterly vesting dates thereafter, subject to continued service. F2 reiterates the securities are RSUs.
  • F3: Separately describes an option vesting schedule (25% vest Feb 4, 2027, then 1/48th monthly thereafter); appears to apply to option-type awards and may reflect other equity arrangements.
• Filing timeliness: Form filed two days after the grant date (Feb 6 filing for Feb 4 report); no late-filing flag noted in the provided data.

Context

• RSUs are compensation awards that convert into shares only as they vest; they are not immediate cash purchases or open-market trades. These grants reflect executive compensation/retention mechanics rather than a direct bullish or bearish market signal.
• For retail investors, vesting schedules determine when the CFO may acquire actual shares; any future sale would be reported separately.